The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sat., Apr. 30, 10:15 PM

Slide #10. DURECT Corporation Secondary Offering

Company: DURECT Corporation (NASDAQ:DRRX)
Date announced: 4/25/2016
Shares Offered: 12,000,000
Date of Pricing: 4/26/2016
Price Per Share: $1.25
Secondary Offering Details: DURECT Corporation (Nasdaq: DRRX) today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering. DURECT anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs and to meet working capital needs. All of the shares in the offering are to be sold by DURECT. - updated 4/26 - DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, offered at a price of $1.25 per share to the public. The gross proceeds to DURECT from this offering are expected to be $15 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by DURECT. All of the shares in the offering are to be sold by DURECT. The offering is expected to close on or about April 29, 2016, subject to the satisfaction of customary closing conditions. DURECT has granted the underwriters a 30-day option to purchase up to an aggregate of 1,800,000 additional shares.

DURECT is a pharmaceutical company focused on the development of pharmaceuticals based on its proprietary drug delivery technology platforms. At Dec 31 2014, Co. had seven investigational drug candidates in clinical development. The more developed programs are in the field of pain management. Co. has other programs underway in fields outside of pain management, including central nervous system disorders, metabolic disorders, cardiovascular disease, acute organ injury, ophthalmic conditions, and other diseases. Co.'s development activities are focused on the application of its drug delivery technologies to potential products in a variety of chronic and episodic disease areas.

DRRX SEC Filing Email Alerts Service

Open the DRRX Page at The Online Investor »

Company Name:  Durect Corp
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding DRRX:  16
Total Market Value Held by ETFs:  $6.58M
Total Market Capitalization:  $179.00M
% of Market Cap. Held by ETFs:  3.67%

Open the DRRX Page at The Online Investor (in a new window) »

April 30, 2016    10:15 PM Eastern
Quotes delayed 20 minutes

Buy (3.33 out of 4)
61st percentile
(ranked higher than approx. 61% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.